COVID-19 and autoimmune bullous diseases: Lessons learned

Michael Kasperkiewicz; David T Woodley

doi:10.1016/j.autrev.2023.103286

COVID-19 and autoimmune bullous diseases: Lessons learned

Autoimmun Rev. 2023 Apr;22(4):103286. doi: 10.1016/j.autrev.2023.103286. Epub 2023 Feb 2.

Authors

Michael Kasperkiewicz¹, David T Woodley²

Affiliations

¹ Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: Michael.Kasperkiewicz@med.usc.edu.
² Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Abstract

Both COVID-19 and autoimmune bullous diseases represent potentially life-threatening conditions. Autoimmunity has been a special focus during the COVID-19 pandemic considering the possible detrimental mutual influence between COVID-19 and autoimmune disorders as well as their supposed induction or triggering by SARS-CoV-2 vaccines. There is a growing need to assess the impact of the current pandemic particularly in patients with autoimmune bullous diseases requiring potent and long-term immunosuppressive treatments. This review provides the relevant state-of-the-art knowledge, including our own research, about immunobullous diseases in relation to COVID-19 and summarizes expert perspectives on their management throughout the pandemic.

Keywords: COVID-19; Pemphigoid; Pemphigus; SARS-CoV-2.

Publication types

Review

MeSH terms

Autoimmune Diseases* / epidemiology
COVID-19 Vaccines
COVID-19* / epidemiology
Humans
Pandemics
Pemphigoid, Bullous*
Pemphigus*
SARS-CoV-2

Substances

COVID-19 Vaccines